Beam Therapeutics (BEAM) Non-Current Deffered Revenue (2020 - 2025)

Beam Therapeutics (BEAM) has 6 years of Non-Current Deffered Revenue data on file, last reported at $10.2 million in Q3 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 82.43% year-over-year to $10.2 million in Q3 2025; TTM through Sep 2025 was $10.2 million, a 82.43% decrease from a year earlier, with the FY2024 full-year figure at $33.2 million, down 69.77% from the prior year.
• Non-Current Deffered Revenue for Q3 2025 stood at $10.2 million, down from $20.3 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for BEAM reached as high as $262.3 million in Q4 2021 and fell as low as $10.2 million in Q3 2025.
• Historically, Non-Current Deffered Revenue has averaged $115.7 million across 5 years, with a median of $104.7 million in 2023.
• Across the five-year window, Non-Current Deffered Revenue jumped 66474.37% in 2021 and slumped 82.43% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $262.3 million in 2021, then slipped by 22.92% to $202.2 million in 2022, then plunged by 45.65% to $109.9 million in 2023, then sank by 69.77% to $33.2 million in 2024, then slumped by 69.41% to $10.2 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $10.2 million in Q3 2025, $20.3 million in Q2 2025, and $49.4 million in Q1 2025.